Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported strong financial performance in Q3 2025, with revenue of 796 million yuan, a year-on-year increase of 21.88%, and a net profit of 159 million yuan, up 37.86% year-on-year. The Q3 revenue alone was 271 million yuan, reflecting a 23.05% increase year-on-year, with net profit soaring by 74.25% [5][8] - The approval of the Glimepiride sustained-release tablets marks the second innovative generic drug approved in 2025, enhancing the company's product pipeline in the diabetes sector [5][8] - The company maintains a robust gross margin of over 80%, indicating a strong product structure focused on chronic disease treatments, while net profit margins have shown consistent improvement [8][9] Financial Performance Summary - For the first three quarters of 2025, the company achieved a revenue of 796 million yuan, a 21.88% increase year-on-year, and a net profit of 159 million yuan, a 37.86% increase year-on-year. The gross margin stood at 84.10%, with a net margin of 19.97% [5][8] - The Q3 results showed a revenue of 271 million yuan, a 23.05% increase year-on-year, and a net profit of 61.14 million yuan, a significant increase of 74.25% year-on-year [5][8] - The company forecasts revenues of 1,055.79 million yuan, 1,209.62 million yuan, and 1,451.55 million yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 227.92 million yuan, 264.70 million yuan, and 311.13 million yuan [9][10] Product Development and Pipeline - The company emphasizes a research and development strategy that combines generics and innovation, focusing on expanding its product pipeline in chronic diseases and metabolic syndromes [8][9] - Key innovative drugs in development include DYX116 and DYX216, with DYX116 currently in Phase I clinical trials and DYX216 targeting treatment for resistant hypertension [8][9]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [7]. Core Views - The company has shown resilience with a revenue growth of 7.12% year-on-year for the first three quarters of 2025, despite facing pressure in Q3 with a revenue decline of 18.88% [4][6]. - The company is focusing on accelerating capacity release and optimizing operational expenses to enhance profitability [6]. - The upgraded fundraising project aims to expand production capacity significantly, targeting a total investment of 7.08 billion yuan, which will enhance the company's capabilities in producing various active pharmaceutical ingredients [6]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 211 million yuan, with a net profit of approximately 45.95 million yuan, reflecting a year-on-year increase of 22.85% [4][6]. - The gross margin for the first three quarters was 41.23%, up by 2.84 percentage points year-on-year, while the net margin was 20.48%, an increase of 2.27 percentage points year-on-year [6]. - In Q3 alone, the company reported a revenue of 48.14 million yuan, down 18.88% year-on-year, and a net profit of 5.52 million yuan, down 33.29% year-on-year [4][6]. Investment Highlights - The company is transitioning to a more integrated manufacturing platform by expanding its production capabilities in active pharmaceutical ingredients and formulations, which is expected to support international partnerships [6]. - The projected revenues for 2025-2027 are 328.40 million, 412.83 million, and 485.61 million yuan, respectively, with corresponding net profits of 69.45 million, 86.08 million, and 92.70 million yuan [6][8]. - The current market valuation corresponds to a PE ratio of 25.64 for 2025, indicating a favorable investment opportunity based on expected growth [6][8].

Investment Rating - The report assigns an investment rating of "Buy (First Coverage)" with a current price of 64.70 CNY and a target price of 101.82 CNY over a 12-month period [1][5]. Core Insights - The report highlights that the IDE (Integrated Development Environment) business is expected to be the core growth driver for the company, with significant revenue growth projected from 2025 to 2027 [5][33]. - The company is strategically positioned in the AI and programming sector, leveraging AI technologies to enhance its IDE products [5][27]. - The global software development tools market is projected to grow from 6.517 billion USD in 2025 to 14.680 billion USD by 2031, with a CAGR of 14.5% [28]. Company Overview - The report details that Jiangsu Zhuoyi Information Technology Co., Ltd. was established in May 2008 and went public on the Shanghai Stock Exchange in December 2019 [13][19]. - The company’s main business segments include IDE business, core firmware for cloud computing devices, and cloud services [13][33]. Financial Performance - The company’s projected revenues for 2025, 2026, and 2027 are 414.33 million CNY, 583.64 million CNY, and 827.17 million CNY, respectively, with year-on-year growth rates of 28.12%, 40.87%, and 41.72% [6][5]. - The net profit attributable to the parent company is expected to reach 93.87 million CNY in 2025, 154.42 million CNY in 2026, and 289.99 million CNY in 2027, with significant growth rates of 185.84%, 64.50%, and 87.79% [6][5]. IDE Industry Analysis - The IDE industry is characterized by a deep integration with AI technologies, enhancing development efficiency and reducing errors [27][31]. - The report notes that the current market for IDEs is dominated by foreign companies, with a lack of domestic players capable of mature IDE development and commercialization [27][28]. - Key trends in the IDE industry include AI programming support, low-code technology applications, and cloud-native support [31][32]. Business Segments - The company’s IDE products include SnapDevelop, EazyDevelop, PowerBuilder, and PowerServer, targeting various customer segments including large enterprises and independent software developers [36][37]. - The cloud computing firmware business provides essential BIOS and BMC firmware for computing devices, serving major clients like Intel and Huawei [44][45]. - The cloud services segment focuses on IoT cloud services, primarily targeting government and enterprise clients [47]. Management and Ownership - The report indicates that the company is controlled by its actual controllers, Xie Qian and Wang Ye, who together hold a 40.74% stake [20][23]. - The core management team has a strong educational background and stability, with key figures having long tenures in the company [23][24]. Stock Incentive Plan - In May 2025, the company announced a stock incentive plan aimed at core technical and key personnel, with performance targets set for the IDE business from 2025 to 2027 [25][26].

Investment Rating - The industry investment rating is "Overweight" (maintained) [5] Core Insights - The approval of Aidi Pharmaceutical's core product, Dolutegravir Sodium, marks a significant breakthrough in the vertical integration of the anti-HIV drug supply chain, enhancing the company's competitiveness and cost control in the domestic market [5][7] - The approval aligns with national policies encouraging innovation in the pharmaceutical industry and supports the high-quality development of the biopharmaceutical sector, showcasing the increasing R&D capabilities of domestic pharmaceutical companies [7] Summary by Sections Recent Industry Performance - Over the past 12 months, the industry has shown a relative return of -7.19% compared to the CSI 300 index, with absolute returns of 13.9% [3] Key Events - Aidi Pharmaceutical announced the approval of its core product, Dolutegravir Sodium, by the National Medical Products Administration (NMPA), which is a key drug in the WHO's first-line treatment for HIV [5][6] Investment Recommendations - The report suggests focusing on other antiviral companies, particularly those with existing products or strong R&D capabilities in chronic viral diseases like HIV and hepatitis B [7] - It also recommends investing in specialty raw material and CDMO companies, highlighting the value of firms with high-quality standards and technological barriers [7]

Investment Rating - The industry investment rating is "Overweight" (maintained) [5] Core Insights - The report highlights the recent policy issued by the Ningxia Hui Autonomous Region government aimed at enhancing the regulatory framework for pharmaceuticals and medical devices, which is expected to promote high-quality development in the pharmaceutical industry [5] - The policy emphasizes support for the entire chain of traditional Chinese medicine (TCM) innovation, particularly focusing on the protection and development of local resources such as goji berries and licorice, which will benefit local TCM enterprises [6] - The report suggests that the policy will significantly improve the efficiency of product approvals for innovative drugs and medical devices, with specific measures to shorten approval timelines [6] - The report recommends focusing on companies with existing operations in Ningxia, especially those involved in the deep processing of local TCM resources, as well as innovative drug and medical device developers [6] Summary by Sections Recent Industry Performance - The industry has shown relative returns of -4.75% over the past month, -17.32% over the past three months, and -7.19% over the past year compared to the CSI 300 index [3] Policy Impact - The Ningxia policy includes measures to enhance the approval process for innovative drugs and medical devices, reducing the approval time for medical device production licenses from 30 to 20 working days and for second-class medical device renewals from 60 to 50 working days [6] - The policy encourages collaboration among local enterprises, universities, research institutions, and medical organizations to foster innovation in drug and medical device development [6] Investment Recommendations - The report advises investors to pay attention to companies that have a strong presence in Ningxia, particularly those involved in the development of local TCM resources, as well as those engaged in innovative drug and medical device research [6] - Specific companies mentioned for potential investment include Tongrentang, Dong'e Ejiao, Mindray Medical, Jiuzhoutong, and Tigermed [6]

证券研究报告·公司点评报告 2025 年 10 月 31 日 江海证券研究发展部 执业证书编号：S1410525010001 联系人：刘瑜 执业证书编号：S1410123110011 | 投资评级： | 增持（维持） | | --- | --- | | 当前价格: | 27.06元 | | 总股本(百万股) | 70.95 | | --- | --- | | A 股股本(百万股) | 70.95 | | B/H 股股本(百万股) | -/- | | A 股流通比例(%) | 62.18 | | 12 个月最高/最低(元) | 38.98/16.85 | | 第一大股东 | 朱湘军 | | 第一大股东持股比例(%) | 43.70 | | 上证综指/沪深 300 | 3986.90/4709.91 | % 1 个月 3 个月 12 个月 相对收益 1.76 -7.71 14.03 绝对收益 2.66 0.19 34.60 数据来源：聚源 注：相对收益与北证 50 相比 1. 江海证券-公司深度报告（首次覆盖）- 视声智能：KNX 总线智能家居品牌，提供 住宅与建筑智能化解决方案 – 2025.05.13 分析师 ...

Investment Rating - The report assigns an investment rating of "Buy (First Coverage)" with a current price of 64.70 CNY and a target price of 101.82 CNY over a 12-month period [1][5]. Core Insights - The report highlights that the IDE (Integrated Development Environment) business is expected to be the core growth driver for the company, with significant revenue growth projected from 2025 to 2027 [5][33]. - The company is strategically positioned in the AI and programming sector, leveraging AI technologies to enhance its IDE offerings [5][27]. - The global software development tools market is projected to grow from 6.517 billion USD in 2025 to 14.680 billion USD by 2031, with a CAGR of 14.5% [5][28]. Company Overview - The report details that Jiangsu Zhaoyi Information Technology Co., Ltd. was established in May 2008 and went public on the Shanghai Stock Exchange in December 2019 [13][19]. - The company’s main business segments include IDE business, core firmware for cloud computing devices, and cloud services [13][33]. Financial Performance - The company’s revenue is projected to grow from 414.33 million CNY in 2025 to 827.17 million CNY in 2027, with corresponding net profits expected to rise from 93.87 million CNY to 289.99 million CNY during the same period [6][5]. - The report provides a detailed financial forecast, indicating a significant increase in both revenue and net profit over the next three years [6][5]. Business Analysis - The IDE business is identified as a key area for future growth, with products like SnapDevelop and EazyDevelop being central to the company's strategy [5][36]. - The company has a dual strategy of "IDE+AI" and "AI+IDE," focusing on enhancing development efficiency through AI integration [5][36]. - The report notes that the company has a strong management team with a stable background, which is crucial for executing its growth strategy [5][23]. Industry Analysis - The IDE industry is undergoing significant transformation due to advancements in AI, cloud computing, and low-code technologies, which are expected to drive future growth [27][31]. - The report emphasizes the scarcity of domestic companies with mature IDE development capabilities, positioning the company as a rare player in the market [27][28].

Report Industry Investment Rating - The document does not provide the report industry investment rating [1][2] Core Views - With the improvement of the China-Europe Railway Express control system, the completion of the capacity expansion and upgrading of cross-border railway lines in Heilongjiang, and the stabilization of the overseas political situation, Heilongjiang's import and export trade will be further enhanced, supporting the long-term stable development of the provincial economy [3][9] - In the A-share market sentiment continues to warm up and the domestic economic improvement trend is more clear, listed companies in Heilongjiang Province are expected to maintain good performance [3][20] - As China's economic structure transformation deepens, the consumer market demand is expected to continue to improve [34] Summary by Directory 1. Heilongjiang Current News Tracking - As of October 24, 2025, the import volume of Tongjiang Railway Port reached 517 million tons, setting a new high for the same period. The port has taken measures to improve customs clearance and transportation efficiency, and the ongoing upgrade projects are expected to increase the cargo throughput by 40% and enrich the categories of imported and exported goods [3][9] - The 27th Harbin Ice and Snow World is upcoming, with the largest area in history, more ice and snow sculptures, diverse technological elements, and expanded entertainment and performance projects. The standard adult ticket price remains at 328 yuan, and the pre-sale tickets are on sale [10] - Since the 14th Five-Year Plan, Heilongjiang Province has made breakthroughs in scientific and technological research, with 16 billion yuan invested in key R & D programs. In the future, it will strengthen organized scientific research to support the construction of a modern industrial system [11][12] 2. Financial Market Data Tracking - Since October, the Korea Composite Index and the Nikkei 225 have led in returns, while the ChiNext Index and the Hang Seng Index in China have declined. Among industries, coal, banking, and power equipment have performed well, while media, automotive, and computer sectors have adjusted [13][14] - From October 20 to 24, the Shanghai Composite Index stood above 3900 points again, with most sectors rising. The communication and electronics sectors were the most prominent [17] - Since October, the Heilongjiang sector index has risen by 3.81%, with 29 listed companies achieving positive returns and 10 declining in the statistical period. Some companies like Baotailong had significant increases [3][18][20] 3. Domestic Macroeconomic Data Operation - In September, China's industrial added value above designated size increased by 6.5% year-on-year and 0.64% month-on-month. Different industries and economic types showed varying degrees of growth, indicating an overall improvement in business conditions [22][23] - In the first three quarters of 2025, the national fixed - asset investment (excluding rural households) decreased by 0.5% year-on-year, with different trends in different industries [29] - In September, the total retail sales of consumer goods were 4.1971 trillion yuan, a year-on-year increase of 3.0%. From January to September, the cumulative total was 36.5877 trillion yuan, with a year-on-year increase of 4.5%, showing the activation of market vitality and the release of consumption potential [32]

- The report tracks the performance of broad-based indices in the A-share market, noting that all indices rose on October 29, 2025, with the ChiNext Index (2.93%) and the CSI 500 (1.91%) showing the largest gains[1][2] - The ChiNext Index has the highest year-to-date increase (55.22%), followed by the CSI 2000 (32.8%) and the CSI 500 (30.66%)[2] - All tracked indices are above their 5-day, 10-day, and 20-day moving averages, with the ChiNext Index and the CSI 300 having substantial support from these averages[13] - The CSI 300 had the highest trading volume share on October 29, 2025 (29.12%), followed by the CSI 2000 (20.79%) and the CSI 500 (19.98%)[16] - The ChiNext Index has the highest negative skewness and kurtosis deviation, indicating a higher concentration of returns and more extreme negative returns[23][24] - The risk premium for the CSI 500 (96.03%) and the ChiNext Index (95.4%) is relatively high compared to the past five years, while the SSE 50 (69.84%) and the CSI 2000 (54.52%) are lower[27][30] - The PE-TTM ratios for the CSI 500 (98.68%) and the CSI All Share Index (98.84%) are high, while the CSI 2000 (83.72%) and the ChiNext Index (61.98%) are lower[36][39][40] - The dividend yield for the ChiNext Index (62.23%) and the CSI 1000 (35.62%) is relatively high, while the CSI 2000 (16.12%) and the CSI 500 (12.56%) are lower[47][49] - The current net break rate for indices is highest for the SSE 50 (22.0%) and lowest for the ChiNext Index (1.0%)[51]

Investment Rating - The investment rating for the company is upgraded to "Accumulate" [4] Core Views - The company reported a revenue of 1.378 billion yuan for the first three quarters of 2025, a year-on-year increase of 1.00%, while the net profit attributable to shareholders decreased by 34.06% to 54 million yuan [4] - The third quarter of 2025 saw a revenue of 492 million yuan, reflecting a year-on-year increase of 4.27% and a quarter-on-quarter increase of 18.55% [4] - The company is expected to achieve revenue growth rates of 3.48%, 5.38%, and 8.70% for the years 2025, 2026, and 2027 respectively [9] Financial Performance Summary - For the first three quarters of 2025, the gross margin was 22.73%, a decrease of 1.52 percentage points year-on-year, and the net margin was 3.88%, down by 2.05 percentage points year-on-year [9] - The company’s sales expense ratio increased to 6.10%, primarily due to increased costs associated with e-commerce channels and new retail sales personnel [9] - The forecasted total revenue for 2025 is 1.934 billion yuan, with a projected net profit of 86.25 million yuan [7][9] - The company aims to enhance its gross margin by establishing deeper collaborations with major clients such as Hema, Walmart, and Yonghui [9]